Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment

Background: Patients with type 1 diabetes mellitus (T1DM) may have suboptimal glucose control and are interested in the use of adjuvant therapies. Objectives: To determine, from the patients’ perspective, the reasons for initiation of glucagon-like peptide 1 receptor agonist (GLP-1RA) and/or sodium...

Full description

Bibliographic Details
Published in:	Therapeutic Advances in Endocrinology and Metabolism
Main Authors:	Khary Edwards, Aleksandra Uruska, Anna Duda-Sobczak, Dorota Zozulinska-Ziolkiewicz, Ildiko Lingvay
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-06-01
Online Access:	https://doi.org/10.1177/20420188231180987

Similar Items

Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report
by: Agnieszka Gandecka-Pempera, et al.
Published: (2025-10-01)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
by: Bartosz Rolek, et al.
Published: (2023-07-01)

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
by: Aryan Gajjar, et al.
Published: (2025-08-01)

Molecular Changes in Cells of Patients with Type 2 Diabetes Mellitus Depending on Changes in Glycemia Level in the Context of Lifestyle—An Overview of the Latest Scientific Discoveries
by: Magdalena Szczechla, et al.
Published: (2023-02-01)

SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes
by: Jae-Han Jeon
Published: (2024-03-01)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023-03-01)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
by: Rahul S. Dadwani, et al.
Published: (2023-07-01)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
by: Soraya Puglisi, et al.
Published: (2021-10-01)

Is it time to change the goals of lipid management in type 1 diabetes mellitus? Changes in apolipoprotein levels during the first year of type 1 diabetes mellitus. Prospective InLipoDiab1 study
by: Aleksandra Cieluch, et al.
Published: (2020-10-01)

Higher NADH Dehydrogenase [Ubiquinone] Iron–Sulfur Protein 8 (NDUFS8) Serum Levels Correlate with Better Insulin Sensitivity in Type 1 Diabetes
by: Justyna Flotyńska, et al.
Published: (2022-08-01)

Clinical remission in newly diagnosed type 1 diabetes mellitus and HDL function on cholesterol efflux capacity: prospective InLipoDiab1 study
by: Aleksandra Uruska, et al.
Published: (2025-06-01)

SGLT2 inhibitors and GLP-1 receptor agonists: impact on mortality in diabetic patients with cardiovascular disease
by: Ziad Arow, et al.
Published: (2025-08-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

Influence of Chlorhexidine and Cetylpyridine on Periodontal Status and Indicators of Oxidative Stress in Patients with Type 1 Diabetes
by: Jakub Lipski, et al.
Published: (2021-10-01)

Factors influencing the selection of an SGLT2i vs. a GLP-1RA as cardioprotective agent in patients with type 2 diabetes
by: Shubham Agarwal, et al.
Published: (2025-05-01)

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
by: Jae Hyun Bae
Published: (2025-05-01)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
by: Christopher El Mouhayyar, et al.
Published: (2020-01-01)

Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system
by: Demetria M. Bolden, et al.
Published: (2025-06-01)

An updated perspective and pooled analysis of cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors
by: Mustafa Kılıçkap, et al.
Published: (2021-02-01)

A retrospective analysis of combination therapy with GLP-1 receptor agonists and SGLT2 inhibitors versus SGLT2 inhibitor monotherapy in patients with MASLD
by: Jheng-Yan Wu, et al.
Published: (2025-08-01)

Diabetic Neuropathy Is Related to Rhinencephalon Degeneration in Adults With Type 1 Diabetes
by: Maciej Chudzinski, et al.
Published: (2024-01-01)

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
by: Cheney C, et al.
Published: (2025-05-01)

Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists
by: Nicola Cosentino, et al.
Published: (2025-08-01)

Cardio-Renal Benefits of GLP-1 Receptor Agonists vs. SGLT-2 Inhibitors in Type 2 Diabetes: Are They Juxtaposed?
by: Awadhesh Kumar Singh, et al.
Published: (2022-08-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Revolutionizing cardiometabolic health: the dual power of GLP-1 receptor agonists and SGLT2 inhibitors: a review article
by: G. Tomova-Lyutakova, et al.
Published: (2024-12-01)

Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists
by: Veronika A. Myasoedova, et al.
Published: (2023-12-01)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
by: Suzanne V. Arnold, et al.
Published: (2022-04-01)

Better Cardiorespiratory Fitness Defined as VOmax Increases the Chance of Partial Clinical Remission and Prolongs Remission Duration in People with Newly Diagnosed Type 1 Diabetes
by: Justyna Flotyńska, et al.
Published: (2024-04-01)

Hepatoprotective Benefits of SGLT-2 Inhibitors and GLP-1 Analogs
by: Divya Rajagopal, et al.
Published: (2024-10-01)

GLP-1, SGLT-2, new devices for interventional cardiologists
by: Çetin Erol
Published: (2021-02-01)

Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?
by: Paschalis Karakasis, et al.
Published: (2024-11-01)

An Update on GLP‐1 Receptor Agonists
by: Zachary Bloomgarden
Published: (2025-08-01)

GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?
by: Georgios S Papaetis
Published: (2023-02-01)

Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetesResearch in context
by: Luis A. Rodriguez, et al.
Published: (2024-06-01)

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
by: Dion R. P. Muller, et al.
Published: (2023-10-01)

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
by: Omar Dzaye, et al.
Published: (2022-07-01)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
by: Marta Baviera, et al.
Published: (2022-08-01)

Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01)

Arterial stiffness and the non-dipping pattern in type 1 diabetes males with and without erectile dysfunction
by: Michał Kulecki, et al.
Published: (2023-05-01)